Overview

Aripiprazole in Adolescents With Schizophrenia

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Treatments:

Aripiprazole